Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100945 · ClinicalTrials.gov registry record · Phase 2
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
A Phase 2 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00100945 is a Phase 2 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 70 participants.
The verdict
NCT00100945, a Phase 2 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with locally advanced esophageal cancer.
Interventions
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2005-07 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00100945
The ClinicalTrials.gov registry entry for NCT00100945 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which gefitinib is the first listed.
NCT00100945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00100945 about?
NCT00100945 is a clinical study titled "Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer". RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with locally advanced esophageal cancer.
What is the current status of trial NCT00100945?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2005-07. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00100945?
The interventions under investigation include: gefitinib (DRUG).
Who is sponsoring clinical trial NCT00100945?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.